[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100433145":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":39,"locations":45,"responsibleParty":62,"collaborators":43,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":43,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":43,"overallStatus":47,"whyStopped":43,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of Arizona","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"active TDCS","EXPERIMENTAL","During intervention excitatory\u002Fanodal tDCS will be administered alongside speech-language therapy 5 days a week for 2 weeks. The exact location of the stimulation and electrode configuration will be targeted individually based on the optimal site identified in fMRI. TDCS will be administered with NeurConn1 Channel DC- Stimulator Plus (neuroCare Group, München, Germany) according to established guidelines and procedures. The active tDCS will be delivered for 20 minutes using sponge electrodes with a 30-s ramp-up and ramp-down period",[13],"Combination Product: tDCS + language therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"sham TDCS","SHAM_COMPARATOR","The sham will be administered alongside speech-language therapy 5 days a week for 2 weeks. For sham, stimulation will be ramped up and then down to 0 milliamperes (mA) in the first minute of stimulation. The sham parameters were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade out in the first 30 s of tDCS",[19],"Combination Product: sham TDCS + language therapy",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"COMBINATION_PRODUCT","tDCS + language therapy","In this study fMRI-guided noninvasive neuromodulation will be applied, called Transcranial Direct Current Stimulation (tDCS) to the frontal and parietal brain regions that show reduced activation but still are structurally intact. TDCS will be paired with personalized speech-language therapy to enhance language functions.",[9],[27,28],"active tDCS","transcranial direct current simulation (tDCS)",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"sham TDCS + language therapy","sham control will be applied with language therapy to the same regions as active TDCS.",[15],[34],"sham transcranial direct current simulation (tDCS)",[36],{"name":37,"affiliation":5,"role":38},"Aneta Kielar, PhD","PRINCIPAL_INVESTIGATOR",[40],{"name":37,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","15204883791",null,"akielar@email.arizona.edu",[46],{"facility":5,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Tucson","Arizona","85721-0071","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-110.92648,32.22174,{"lat":57,"lon":56},[60],{"name":37,"role":41,"phone":61,"phoneExt":43,"email":44},"520-488-3791",{"type":63,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100433145","enhancing-language-function-in-primary-progressive-aphasia-100433145",false,"NCT04920318","Enhancing Language Function in Primary Progressive Aphasia","Enhancing Language Function in Primary Progressive Aphasia (PPA) With Transcranial Direct Current Stimulation (tDCS)","PPA","Inclusion Criteria:\n\n* diagnosed with PPA by neurologist or speech-language pathologist\n* speech-language deficit arising from PPA\n* native speaker of English Language or equivalent\n* adequate vision (normal or corrected to normal)\n* adequate hearing\n\nExclusion Criteria:\n\n* meeting (Diagnostic and Statistical Manual) DSM-IV criteria for Axis I mood, anxiety, psychotic or substance abuse disorders.\n* highly magnetizable metallic implants, including certain dental work\n* neurological disorders besides the ones of interest for the study (e.g., epilepsy)\n* Multiple Sclerosis\n* Parkinson's Disease\n* contraindications for MRI\n* pacemakers\n* metallic cardiac pumps\n* valves\n* magnetic materials such as surgical clips, implanted electronic perfusion pumps, or any other condition that would preclude proximity to a strong magnetic field.\n* clinically significant claustrophobia\n* severe systemic disease (e.g., renal failure)\n* poor health\n* pregnancy\n* epileptic activity in the past 12 months\n* family history of epilepsy or other seizure disorders\n* brain surgery in the past\n* metallic skull plates or implants\n* skin lesions or skull damage\n* excessive use of alcohol or drugs\n* premorbid psychiatric disease affecting communication\n* severe non-linguistic cognitive disturbances impeding language therapy","ALL","45 Years","80 Years",{"count":76,"type":77},20,"ESTIMATED","INTERVENTIONAL",[80],"NA","This study's goal is to use non-invasive brain stimulation (NBS) techniques to treat language impairment associated with Primary Progressive Aphasia (PPA). The purpose of this study is to combine behavioral language intervention with individualized noninvasive brain stimulation techniques, called transcranial direct current stimulation (tDCS) to help the brain reorganize around damage and improve language functions.",[83],"Primary Progressive Aphasia","2024-11-26",{"date":86,"type":87},"2024-11-29","ACTUAL",{"date":89,"type":87},"2021-08-30",{"date":91,"type":77},"2027-06-15",{"name":5,"class":6},1]